SCHEMBL17830733

SCHEMBL17830733

O=C(Cn1c(=O)oc2cc(Cl)ccc21)OCc1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
ALDH1A1 P00352 3/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.44
PIK3CB P42338 1/20 0.44
RECQL P46063 1/20 0.44
TP53 P04637 2/20 0.43
LMNA P02545 2/20 0.43
TNIK Q9UKE5 1/20 0.43
KMT2A Q03164 1/20 0.43
GRM5 P41594 1/20 0.43
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
IDO1 P14902 4/20 0.42
TSHR P16473 1/20 0.42
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830732 0.87 USP2 (0.47) MAPTALDH1A1USP2POLBPIK3CB
SCHEMBL17830715 0.87 PIK3CB (0.54) MAPTALDH1A1USP2POLBPIK3CB
SCHEMBL17830725 0.86 POLB (0.52) MAPTALDH1A1USP2POLBPIK3CB
SCHEMBL17830724 0.85 IDO1 (0.51) MAPTALDH1A1USP2POLBPIK3CB
SCHEMBL17830736 0.84 MIF (0.52) MAPTALDH1A1USP2POLBPIK3CB
SCHEMBL17830723 0.82 PKM (0.53) MAPTALDH1A1USP2POLBRECQL
SCHEMBL17830722 0.81 RECQL (0.55) MAPTALDH1A1USP2POLBRECQL
SCHEMBL17830720 0.81 TP53 (0.56) MAPTALDH1A1USP2POLBRECQL
SCHEMBL17830739 0.80 LMNA (0.47) MAPTALDH1A1USP2POLBPIK3CB
SCHEMBL17830729 0.80 CYP1A2 (0.45) MAPTALDH1A1USP2POLBPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A MAPT 2263/4885ALDH1A1 4832/4885USP2 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.